Greenwich LifeSciences (NASDAQ:GLSI) Rating Reiterated by HC Wainwright

Greenwich LifeSciences (NASDAQ:GLSI)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a report issued on Wednesday, Benzinga reports. They currently have a $36.00 target price on the stock. HC Wainwright’s price objective points to a potential upside of 175.23% from the stock’s previous close. HC Wainwright also issued estimates for Greenwich LifeSciences’ Q1 2025 earnings at ($0.17) EPS, Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.17) EPS and FY2025 earnings at ($0.70) EPS.

Greenwich LifeSciences Trading Down 3.1 %

Shares of GLSI opened at $13.08 on Wednesday. The stock has a market cap of $168.47 million, a P/E ratio of -18.17 and a beta of 1.55. Greenwich LifeSciences has a 1 year low of $7.58 and a 1 year high of $21.44. The stock’s 50-day moving average price is $15.37 and its two-hundred day moving average price is $12.52.

Greenwich LifeSciences (NASDAQ:GLSI) last posted its earnings results on Monday, April 15th. The company reported ($0.21) earnings per share (EPS) for the quarter. As a group, equities analysts forecast that Greenwich LifeSciences will post -0.76 EPS for the current year.

Insider Transactions at Greenwich LifeSciences

In other Greenwich LifeSciences news, CEO Snehal Patel acquired 2,500 shares of the firm’s stock in a transaction that occurred on Friday, March 22nd. The stock was acquired at an average cost of $19.98 per share, for a total transaction of $49,950.00. Following the transaction, the chief executive officer now owns 5,347,777 shares of the company’s stock, valued at $106,848,584.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders purchased 11,100 shares of company stock worth $187,133. 52.86% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Greenwich LifeSciences

An institutional investor recently raised its position in Greenwich LifeSciences stock. Vanguard Group Inc. raised its position in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) by 0.6% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 223,102 shares of the company’s stock after acquiring an additional 1,420 shares during the period. Vanguard Group Inc. owned about 1.73% of Greenwich LifeSciences worth $4,449,000 as of its most recent filing with the SEC. Institutional investors own 4.16% of the company’s stock.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.